Founder-led sales for Series A companies: the 90-day install for healthcare and life sciences in emerging markets
The exact 90-day plan for standing up founder-led sales at Series A — the point where the founder can no longer be every function. Written for commercial leaders at healthtech, medtech, and life-sciences companies in emerging markets.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in emerging markets. In this market, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint, so the way you install founder-led sales has to be shaped to that reality from day one.
Series A is the moment founder-led sales stops being optional. The founder has to step out of some of the work, the plan requires a defensible growth number, and every quarter compounds toward the next raise.
Day 1 to 30: diagnosis and instrumentation. Name the constraint, write the ICP, wire founder hours per week in customer conversations into the board pack.
Day 31 to 60: first live cycle at 20% of planned volume. Founder still in every review. Kill criteria written and enforced.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in emerging markets it is compounded by the fact that operating footprint and pricing fit, not brand awareness is what actually gates growth. Founder-led sales is only useful here when it is pointed at both constraints at once.
Day 61 to 90: ramp to full volume, hire the first dedicated operator, and hand off ops. Founder retains strategy and the weekly review.
By day 90 the metric is legible and the trajectory is defensible. This is what turns a Series A story into a Series B round.
Trap most Series A companies fall into: hiring VP of Sales at $500k ARR to escape sales. It usually shows up around day 45 when the founder tries to hire ahead of the model.
The Series A version of founder-led sales looks small compared to what you will build at Series B. That is the point — it is a foundation, not a monument.
Concretely for healthcare and life sciences in emerging markets: the healthcare teams that install this get past procurement instead of dying in it, and the teams that install this early own the category before Western vendors even show up. That is the reason it is worth installing founder-led sales deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Sales · healthcare · emerging markets — answered
- Does founder-led sales work for healthcare and life sciences in emerging markets?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint. The healthcare teams that install this get past procurement instead of dying in it.
- Should we start founder-led sales before Series A?
- Yes if the founder has time; the Series A version is the same model at higher spend.
- How much of the round should fund founder-led sales?
- Meaningful — often 20–30% of the growth line — but only after diagnosis.
- When do we hire the first founder-led sales operator?
- Around day 60, once the model has run one full cycle with the founder.
- What Series A trap should we avoid?
- Hiring VP of Sales at $500k ARR to escape sales — usually a premature senior hire.
- What is the emerging markets-specific pitfall when running founder-led sales for healthcare?
- Importing a playbook that was built for another market. In emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint — the install has to reflect that.
Growth Broker editorial
Filed under sales · healthcare · emerging markets